Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...